AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03951766 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smiling Instead of Smoking (SiS) App Version 2
Description: The investigators have developed a smartphone app that acts as a behavioral, in-the-pocket coach and uses positive psychology exercises to enhance quitting success. It is anonymous, portable, and provides just-in-time support, an important feature for smokers who smoke under specific conditions and circumstances. To support treatment, investigators use a positive psychology approach. The smartphone app administers positive psychology exercises to enhance and/or maintain positive affect, which is hypothesized to stimulate nondaily smokers to enact healthier alternatives to smoking by broadening their thought-action repertoire, increasing confidence, and decreasing craving and defensiveness about smoking-related health information.
Study NCT02012036 — intervention group
Intervention type: DRUG
Intervention: Hexvix
Description: As this is a non-interventional study, detection of NMIBC with Hexvix is in a pre-defined group, chosen prior to and independently from the decision to enrol the subject in this study.~The detection with Hexvix should be in accordance with local Summary of Product Characteristics \[SmPC\].~Subjects will be treated in accordance with usual medical practice during their participation in this study, no additional assessment or tests will be required.
Study NCT02596256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
Study NCT02596256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity
Study NCT02596256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity
Study NCT04014751 — intervention group
Intervention type: OTHER
Intervention: Symptom Monitoring Intervention
Description: This study involves a cancer care delivery process improvement component where all cohort participants, at specified timepoints, are assessed for psychological distress, pain, fatigue, physical function, practical and supportive needs, and dietary and nutritional needs. Patients with severe elevations in psychological distress, physical symptoms or those who endorse supportive care and/or dietary needs are triaged in real time to appropriate providers within the health system (i.e., social work, nursing pool, nutrition services) to address elevated scores and/or stated needs. As such, within the context of this process improvement care delivery project, real time referrals function as interventional processes within the health system to route patients to relevant points of care based on their needs.
Study NCT02564744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered as IV Infusion.
Study NCT01915095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: small magnetic pulses will be given to the brain in a non invasive manner.
Study NCT01915095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS
Description: sham or fake stimulation (TMS or rTMS) will be given to the brain in a non invasive manner
Study NCT03898271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual World
Description: Participants will complete a synchronous PTSD training in an immersive virtual world environment.
Study NCT03898271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual World
Description: Participants will complete a synchronous PTSD training in an immersive virtual world environment.
Study NCT00515528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4-peptide melanoma vaccine
Description: Experimental cancer vaccine given as a shot under the skin once every two weeks
Study NCT00515528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontak
Description: A single dose of Ontak given as an intravenous infusion over 30 minutes, 4 days before the first vaccine is given.
Study NCT01506557 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: dose 800 IU/day for 6 month
Study NCT01915095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: at the direction of the researcher the participant will be instructed to do repetitive motor movements with their arm, hand or leg. this is called training
Study NCT01506557 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oil capsules
Study NCT01345929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-201
Description: CXA-201 IV infusion (1500mg q8) for 7 days
Study NCT01345929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin IV infusion (750mg qd) for 7 days
Study NCT02345655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: urine drug testing
Description: Performed a OS-UDT test in general practice on patients starting buprenorphine
Study NCT02345655 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no test
Description: normal procedure decided by the general practitioner
Study NCT00334568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone XR (extended release) oral tablets
Description: Rosi XR tablets
Study NCT01915095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor Task
Description: participants will be asked to perform specific motor tasks or movements with their fingers, hands, arms or legs.
Study NCT04666025 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of nasopharyngeal swabs, blood, and saliva samples
Study NCT00334568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03706768 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glycocalyx
Description: Measure Degradation of the Glycocalyx
Study NCT04666025 — intervention group
Intervention type: OTHER
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04666025 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical charts are reviewed
Study NCT04666025 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT04651465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuning in to Kids
Description: A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
Study NCT03211663 — intervention group
Intervention type: DEVICE
Intervention: MOTO Medial® UKA
Description: Knee replacement surgery with the MOTO Medial® UKA
Study NCT01393795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qutenza
Description: 8% patch
Study NCT01393795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tegaderm
Description: No active drug
Study NCT01405703 — intervention group
Intervention type: OTHER
Intervention: xrays
Description: xrays from 2 week postop to 5 year postop
Study NCT01266226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous conditioned plasma
Description: 4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
Study NCT01266226 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: 4mL saline application under the footprint following an arthroscopic repair of the rotator cuff.
Study NCT03125330 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Professional coaching
Description: Professional coaching is provided by the Principal Investigator via video conference.
Study NCT01674946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: intraduodenal perfusion
Study NCT01674946 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: intraduodenal perfusion
Study NCT03125330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional coaching
Description: Professional coaching is provided by the Principal Investigator via video conference.
Study NCT04612829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medistus Antivirus Lozenges
Description: A blend of Kistosyn Extract with Gum Arabic
Study NCT04051749 — intervention group
Intervention type: PROCEDURE
Intervention: Noncardiac Vascular Surgery
Description: Noncardiac Vascular Surgery
Study NCT03873727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar13 (PCV13) and Pneumovax (PPS23)
Description: One dose of PCV13 at Month 0 and one dose of PPS23 at Month 12
Study NCT03873727 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo / Pneumovax (PPS23)
Description: One dose of Placebo at Month 0 and one dose of PPS23 at Month 12
Study NCT03873727 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sample
Description: an additional 5 mL sample of blood at one of the visits, preferably at the first visit, concerning patients included in Parisian centers who did not participate in SPLENEVAC 1 study.
Study NCT03873727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: an additional 5 mL sample of blood at one of the visits, preferably at the first visit, concerning patients included in Parisian centers who did not participate in SPLENEVAC 1 study.
Study NCT03188263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright Light
Description: 1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance is 230 μW/m2 and lux is 500 lux.
Study NCT03188263 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dim Light
Description: 1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance in this dimmed is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
Study NCT00170326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dual-chamber pacemaker implantation
Description: Dual Chamber pacing via conventional DDD(R) right ventricular pacemaker or in case of ICD indication a standard dualchamber ICD device.
Study NCT00170326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biventricular dual-chamber pacemaker implant
Description: Biventricular pacemaker system or in case in ICD indication a BIV ICD
Study NCT03748589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngeal mask airway
Description: i-gel laryngeal mask airway is a supraglottic airway device made from a medical grade thermoplastic elastomer , is a non-inflatable device to create anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures and avoid compression trauma.
Study NCT00122616 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alpha-2a (Pegasys®)
Description: Peg-Interferon Alpha2a by subcutaneous injection, 180µg, once weekly
Study NCT00122616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin: tablet oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over 75 kg, once daily
Study NCT00122616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HIV antiretroviral therapy
Description: All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
Study NCT00122616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HIV antiretroviral therapy
Description: All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
Study NCT01946633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic-controlled capsule endoscopy(Navicam)
Study NCT01277822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan (+) amlodipine
Description: One tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks.
Study NCT01277822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match losartan/amlodipine tablets
Description: One tablet containing placebo, orally, once daily, for 8 weeks.
Study NCT01277822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine camsylate
Description: 2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks.
Study NCT01277822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match amlodipine
Description: 2 tablets containing placebo, orally, once daily, for 8 weeks.
Study NCT01901614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LALAK
Description: 1. A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~2. The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed.
Study NCT01901614 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IEK
Description: 1. A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~2. In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed.
Study NCT01901614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retrobulbar Block or General Anesthesia
Study NCT01901614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical coherence tomography (OCT)
Description: OCT will be used to guide the depth of the graft and donor dissections.
Study NCT01901614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Anesthesia
Study NCT01901614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: femtosecond laser
Description: The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
Study NCT01901614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: femtosecond laser
Description: The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
Study NCT04449107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Android based mobile phone application
Description: An android based mobile application will be developed. The application will have features and capacity for text messages, voice messages, pictorial messages and video messages. The content of the messages will be according to the findings of Paigham e sehat project and the four messages domains would be educational, reminder, religious and adverse effects. In addition, pictorial and video messages would be used as per freely available through EPI programme Pakistan.
Study NCT03619434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femtosecond Laser
Description: The laser will be used to make incisions in the cornea for the graft.
Study NCT03619434 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trephine blade
Description: A trephine blade will be used to make incisions in the cornea for the graft
Study NCT01299467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active (PF-03526299)
Description: Capsules for inhalation, 1.396 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
Study NCT01299467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active (PF-03526299)
Description: Capsules for inhalation, 1.396 mg twice a day for up to 12 days. Last dose given 8 hrs before allergen challenge
Study NCT01299467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
Study NCT01299467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active (PF-03526299)
Description: Capsules for inhalation, 4.188 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
Study NCT01674946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bile acid (CDCA, chenodeoxycholic acid)
Description: intraduodenal perfusion
Study NCT01299467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active (PF-03526299)
Description: Capsules for inhalation, 4.188 mg twice a day for up to 12 days. Last dose given 8hrs before allergen challenge
Study NCT02478814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Intake
Description: Amino acid intakes will be varied at 0.2-2.6 g/kg/day
Study NCT01843166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premarin vaginal cream
Description: 2g at bedtime twice weekly
Study NCT01843166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: 2g at bedtime twice weekly
Study NCT01836536 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab standard of care
Description: Standard treatment associated with circulating leucocytes (blood samplings)
Study NCT03081663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quads-Sparing Approach
Description: Quadriceps-sparing mid-vastus approach for total knee arthroplasty
Study NCT03081663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quads-Sparing Approach
Description: Quadriceps-sparing mid-vastus approach for total knee arthroplasty
Study NCT03081663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial Para-Patellar Approach
Description: Medial para-patellar approach for total knee arthroplasty
Study NCT05151159 — intervention group
Intervention type: OTHER
Intervention: immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3
Study NCT01864148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB033
Study NCT01864148 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01864148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex
Study NCT01864148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avonex
Study NCT04670263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tear Film Imager
Description: Tear Film Imager recording
Study NCT04670263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tear Film Imager
Description: Tear Film Imager recording
Study NCT01220401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure, relaxation, and rescription therapy
Description: veterans reporting chronic nightmares at least once per week for the past month who consent to participate will attend four consecutive weekly sessions lasting approximately two hours each. Participants will log their sleep events and associated symptoms (i.e. PTSD, depression, etc.)
Study NCT02702609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: easy-graft CLASSIC
Description: easy-graft will be grafted to a single extraction socket to preserve the ridge dimension for future implant placement.
Study NCT02702609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDBA with collagen plug
Description: FDBA will be grafted to a single extraction socket and covered by collagen plug to preserve the ridge dimension for future implant placement.
Study NCT02997865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped care for depression
Description: Cognitive behavior therapy (CBT), plus referral to the participant's own physician to discuss antidepressant medications if indicated.
Study NCT01060748 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE527
Description: ACE527 comprises a mixture of three live, attenuated ETEC strains; ACAM2025 (CFA/I+ and LTB+), ACAM2022 (CS5+, CS6+ and LTB+), and ACAM2027 (CS1+, CS2+, CS3+ and LTB+). The vaccine is administered orally as a two-dose regimen, at 9x1010 cfu, on Days 0 and 21, in 200 ml CeraVacx buffer. The required volume of each vaccine strain, supplied as a frozen suspension, is mixed into the buffer solution prior to dosing.